2020
DOI: 10.1259/bjr.20200496
|View full text |Cite
|
Sign up to set email alerts
|

Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence

Abstract: Objective: In contrast to traditional views of incurability, patients with oligometastatic disease present with an opportunity for disease eradication with aggressive treatment. There is mounting evidence in investigating the role of stereotactic body radiotherapy (SBRT) in oligometastatic prostate cancer (OMPC). Methods: MEDLINE and EMBASE were queried for prospective cohort studies reporting the outcomes of metachronous OMPC treated with SBRT. The primary outcome was overall local control. Secondary outcomes… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
8
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(10 citation statements)
references
References 41 publications
2
8
0
Order By: Relevance
“…Comparable findings were reported by Yan et al [26] , who identified ten, mainly observational, studies for a total of 653 patients and 1111 metachronous lesions treated with SBRT. Other than confirming both the safety and the efficacy of SBRT in this subset of patients, the authors focused on short- and long-term effects on ADT.…”
Section: Discussionsupporting
confidence: 70%
“…Comparable findings were reported by Yan et al [26] , who identified ten, mainly observational, studies for a total of 653 patients and 1111 metachronous lesions treated with SBRT. Other than confirming both the safety and the efficacy of SBRT in this subset of patients, the authors focused on short- and long-term effects on ADT.…”
Section: Discussionsupporting
confidence: 70%
“…Therefore, our analysis confirms the efficacy of SBRT in providing high LC rates in nodal metastases, even in the setting of PCa oligorecurrences. Finally, in their recent review and meta-analysis [ 42 ], Yan et al reported data on SBRT as MDT in oligometastatic PCa patients, with both LN and bone metastases. The analysis showed 97% overall LC and 39% 2-year PFS, which are consistent with the findings of the present study.…”
Section: Discussionmentioning
confidence: 99%
“…The conceptually similar phase II ORIOLE trial randomized men with OMPC, defined as 1–3 metastases detected using conventional imaging, to SBRT or observation for 6 months and found significantly lower progression of disease at 6 months with SBRT (19% vs. 61%) [35 ▪▪ ]. Yan et al [36] recently performed a meta-analysis of 653 patients from 10 studies treated with SBRT for metachronous OMPC. Overall local control was 97% with median ADT-free survival of 24.7 months and 2-year biochemical progression-free survival of 33%.…”
Section: The Role Of Surgical Metastasis-directed Therapy In Oligomet...mentioning
confidence: 99%